A late-stage medication development company specific in oncology and endocrinology.

Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris stated, ‘We are very happy with AEZS-108 gaining orphan medicinal product designation for ovarian cancers from European authorities, specifically after having been recently granted orphan-drug designation by the FDA. This means that with both these orphan designations, AEZS-108 would be given extra market exclusivity safety in Europe in addition to in the United States for the treatment of ovarian cancer. We now anticipate reporting the final results from our ongoing European Phase 2 research in ovarian and endometrial cancer, this year later.’.. Aeterna Zentaris’ AEZS-108 receives orphan medicinal product designation for ovarian cancers in Europe Aeterna Zentaris Inc. , a late-stage medication development company specific in oncology and endocrinology, today announced that it provides received a positive opinion for orphan medicinal product designation from the Committee for Orphan Medicinal Items of the European Medications Agency, for its compound AEZS-108 for the treatment of ovarian tumor.The ‘Shelter’ research, entitled ‘A proof-of-concept Phase II study to evaluate efficacy, protection and pharmacokinetics of 4SC-201 and of the procedure mix of sorafenib plus 4SC-201 in sufferers with hepatocellular carcinoma exhibiting progressive disease under sorafenib treatment’, will examine whether treatment with 4SC-201 only or in combination with sorafenib , the current standard of care in advanced HCC), can induce progression free tumour and survival responses in HCC individuals who display progressive disease less than treatment with sorafenib.